Supportive Care in Cancer

, Volume 22, Issue 6, pp 1537–1548 | Cite as

Functional benefits are sustained after a program of supervised resistance exercise in cancer patients with bone metastases: longitudinal results of a pilot study

  • Prue CormieEmail author
  • Daniel A. Galvão
  • Nigel Spry
  • David Joseph
  • Dennis R. Taaffe
  • Robert U. Newton
Original Article



Exercise may represent an effective adjunct therapy to current medical management strategies for maintaining functional independence and improving quality of life in cancer patients with bone metastatic disease. However, it has yet to be determined if there are any sustained effects following the completion of an exercise program by patients with bone metastases.


The aim of this study is to determine whether a 3-month supervised resistance exercise program results in any sustained functional benefits in prostate and breast cancer patients with bone metastatic disease.


Twenty men and women with bone metastatic disease secondary to prostate or breast cancer completed a 3-month supervised resistance exercise program followed by a 6-month observation period. Outcomes were assessed at baseline, post-exercise, and 6-month follow-up.


Fourteen participants completed the follow-up observation period. Significant improvements in physical function (4–6 %), physical activity levels (~160 min/week), lean mass (3–4 %), and quality of life (5–7 %) were observed at the completion of the exercise program. At the 6-month follow-up, significant improvements in ambulation (4 %), physical activity level (~105 min/week), whole body lean mass (2 %), and quality of life (13 %) remained.


An appropriately designed and supervised 3-month resistance exercise program may lead to significant improvements in functional ability, physical activity level, lean mass, and quality of life that remain 6 months after completion of the program in cancer patients with bone metastases. Future trials involving larger sample sizes are required to expand these preliminary findings.


Bone metastases Physical activity Advanced cancer Physical function 



This study was funded by Cancer Council of Western Australia through the Early Career Investigator research grants program. PC is supported by the Cancer Council Western Australia Postdoctoral Research Fellowship. DAG is funded by a Movember New Directions Development Award obtained through Prostate Cancer Foundation of Australia's Research Program.

Conflict of interest

The authors have no conflicts of interest to disclose.


  1. 1.
    Abellan van Kan G (2009) Epidemiology and consequences of sarcopenia. J Nutr Health Aging 13:708–712PubMedCrossRefGoogle Scholar
  2. 2.
    Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM (2012) Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J Natl Cancer Inst 104:815–840PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Bjorner JB, Wallenstein GV, Martin MC, Lin P, Blaisdell-Gross B, Tak Piech C, Mody SH (2007) Interpreting score differences in the SF-36 vitality scale: using clinical conditions and functional outcomes to define the minimally important difference. Curr Med Res Opin 23:731–739PubMedCrossRefGoogle Scholar
  4. 4.
    Borg G (1998) Borg's perceived exertion and pain scales. Human Kinetics, ChampaignGoogle Scholar
  5. 5.
    Coleman RE (2001) Metastatic bone disease: clinical features, pathophysiology, and treatment strategies. Cancer Treat Rev 27:165–176PubMedCrossRefGoogle Scholar
  6. 6.
    Coleman RE, Lipton A, Roodman GD, Guise TA, Boyce BF, Brufsky AM, Clezardin P, Croucher PI, Gralow JR, Hadji P, Holen I, Mundy GR, Smith MR, Suva LJ (2010) Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev 36:615–620PubMedCentralPubMedCrossRefGoogle Scholar
  7. 7.
    Cormie P, Newton RU, Spry N, Joseph D, Taaffe DR, Galvao DA (2013) Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases Prostate Cancer and Prostatic Disease Aug 6 [Epub ahead of print]Google Scholar
  8. 8.
    Courneya KS, Friedenreich CM (2011) Physical activity and cancer. In: physical activity and cancer. Springer, City, p 387CrossRefGoogle Scholar
  9. 9.
    Edwards MH, Jameson K, Denison H, Harvey NC, Sayer AA, Dennison EM, Cooper C (2013) Clinical risk factors, bone density, and fall history in the prediction of incident fracture among men and women. Bone 52:541–547PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Ferriolli E, Skipworth RJ, Hendry P, Scott A, Stensteth J, Dahele M, Wall L, Greig C, Fallon M, Strasser F, Preston T, Fearon KC (2012) Physical activity monitoring: a responsive and meaningful patient-centered outcome for surgery, chemotherapy, or radiotherapy? J Pain Symptom Manage 25 Jan [Epub ahead of print]Google Scholar
  11. 11.
    Galvao DA, Nosaka K, Taaffe DR, Spry N, Kristjanson LJ, McGuigan MR, Suzuki K, Yamaya K, Newton RU (2006) Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc 38:2045–2052PubMedCrossRefGoogle Scholar
  12. 12.
    Galvao DA, Spry NA, Taaffe DR, Newton RU, Stanley J, Shannon T, Rowling C, Prince R (2008) Changes in muscle, fat, and bone mass after 36 weeks of maximal androgen blockade for prostate cancer. BJU Int 102:44–47PubMedCrossRefGoogle Scholar
  13. 13.
    Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2009) Cardiovascular and metabolic complications during androgen deprivation: exercise as a potential countermeasure. Prostate Cancer Prostatic Dis 12:233–240PubMedCrossRefGoogle Scholar
  14. 14.
    Galvao DA, Taaffe DR, Spry N, Joseph D, Newton RU (2010) Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol 28:340–347PubMedCrossRefGoogle Scholar
  15. 15.
    Gillespie LD, Robertson MC, Gillespie WJ, Sherrington C, Gates S, Clemson LM, Lamb SE (2012) Interventions for preventing falls in older people living in the community. Cochrane Database Syst Rev 9, CD007146PubMedGoogle Scholar
  16. 16.
    Hechmati G, Cure S, Gouepo A, Hoefeler H, Lorusso V, Luftner D, Duran I, Garzon-Rodriguez C, Ashcroft J, Wei R, Ghelani P, Bahl A (2013) Cost of skeletal-related events in European patients with solid tumors and bone metastases: data from a prospective multinational observational study. J Med Econ 16:691–700PubMedCrossRefGoogle Scholar
  17. 17.
    Higano CS (2008) Androgen-deprivation-therapy-induced fractures in men with nonmetastatic prostate cancer: what do we really know? Nat Clin Pract Urol 5:24–34PubMedCrossRefGoogle Scholar
  18. 18.
    Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA (2005) Physical activity and survival after breast cancer diagnosis. JAMA 293:2479–2486PubMedCrossRefGoogle Scholar
  19. 19.
    Irvin W Jr, Muss HB, Mayer DK (2011) Symptom management in metastatic breast cancer. Oncologist 16:1203–1214PubMedCentralPubMedCrossRefGoogle Scholar
  20. 20.
    Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, Bernstein L, Gilliland FD, Ballard-Barbash R (2005) Changes in body fat and weight after a breast cancer diagnosis: influence of demographic, prognostic, and lifestyle factors. J Clin Oncol 23:774–782PubMedCentralPubMedCrossRefGoogle Scholar
  21. 21.
    Jacobs DR Jr, Ainsworth BE, Hartman TJ, Leon AS (1993) A simultaneous evaluation of ten commonly used physical activity questionnaires. Med Sci Sports Exerc 25:81–91PubMedCrossRefGoogle Scholar
  22. 22.
    Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM (2011) Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol 29:726–732PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Kinnane N (2007) Burden of bone disease. Eur J Oncol Nurs 11:S28–S31PubMedCrossRefGoogle Scholar
  24. 24.
    Li EC, Davis LE (2003) Zoledronic acid: a new parenteral bisphosphonate. Clin Ther 25:2669–2708PubMedCrossRefGoogle Scholar
  25. 25.
    Lipton A (2003) Bisphosphonate therapy in the oncology setting. Expert Opin Emerg Drugs 8:469–488PubMedCrossRefGoogle Scholar
  26. 26.
    Loriot Y, Massard C, Fizazi K (2012) Recent developments in treatments targeting castration-resistant prostate cancer bone metastases. Ann Oncol 23:1085–1094PubMedCrossRefGoogle Scholar
  27. 27.
    Lynch ME, Brooks D, Mohanan S, Lee MJ, Polamraju P, Dent K, Bonassar L, van der Meulen MCH, Fischbach C (2013) In vivotibial compression decreases osteolysis and tumor formation in a human metastatic breast cancer model. J Bone Miner Res 28:2357–2367PubMedCrossRefGoogle Scholar
  28. 28.
    Myers AM, Fletcher PC, Myers AH, Sherk W (1998) Discriminative and evaluative properties of the activities-specific balance confidence (ABC) scale. J Gerontol A Biol Sci Med Sci 53:M287–M294PubMedCrossRefGoogle Scholar
  29. 29.
    National Cancer Institute (2009) Common Terminology Criteria for Adverse Events (CTCAE). U.S. Department of Health and Human Services, National Institute of Health, City, pp. 196Google Scholar
  30. 30.
    Popovic M, Nguyen J, Chen E, Di Giovanni J, Zeng L, Chow E (2012) Comparison of the EORTC QLQ-BM22 and the FACT-BP for assessment of quality of life in cancer patients with bone metastases. Expert Rev Pharmacoecon Outcomes Res 12:213–219PubMedCrossRefGoogle Scholar
  31. 31.
    Price DD, McGrath PA, Rafii A, Buckingham B (1983) The validation of visual analogue scales as ratio scale measures for chronic and experimental pain. Pain 17:45–56PubMedCrossRefGoogle Scholar
  32. 32.
    Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, Bandera EV, Hamilton KK, Grant B, McCullough M, Byers T, Gansler T (2012) Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 62:242–274CrossRefGoogle Scholar
  33. 33.
    Roodman GD (2004) Mechanisms of bone metastasis. N Engl J Med 350:1655–1664PubMedCrossRefGoogle Scholar
  34. 34.
    Saad F, Lipton A, Cook R, Chen YM, Smith M, Coleman R (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860–1867PubMedCrossRefGoogle Scholar
  35. 35.
    Saad F, Olsson C, Schulman CC (2004) Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol 46:731–739, discussion 739-740PubMedCrossRefGoogle Scholar
  36. 36.
    Sayer AA, Syddall HE, Martin HJ, Dennison EM, Anderson FH, Cooper C (2006) Falls, sarcopenia, and growth in early life: findings from the Hertfordshire cohort study. Am J Epidemiol 164:665–671PubMedCentralPubMedCrossRefGoogle Scholar
  37. 37.
    Saylor PJ, Armstrong AJ, Fizazi K, Freedland S, Saad F, Smith MR, Tombal B, Pienta K (2013) New and emerging therapies for bone metastases in genitourinary cancers. Eur Urol 63:309–320PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, Irwin ML, Wolin KY, Segal RJ, Lucia A, Schneider CM, von Gruenigen VE, Schwartz AL (2010) American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 42:1409–1426PubMedCrossRefGoogle Scholar
  39. 39.
    Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, Venner PM, Quinney HA, Jones LW, D'Angelo ME, Wells GA (2003) Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol 21:1653–1659PubMedCrossRefGoogle Scholar
  40. 40.
    Segal RJ, Reid RD, Courneya KS, Sigal RJ, Kenny GP, Prud'Homme DG, Malone SC, Wells GA, Scott CG, Slovinec D'Angelo ME (2009) Randomized controlled trial of resistance or aerobic exercise in men receiving radiation therapy for prostate cancer. J Clin Oncol 27:344–351PubMedCrossRefGoogle Scholar
  41. 41.
    Stein KD, Jacobsen PB, Blanchard CM, Thors C (2004) Further validation of the multidimensional fatigue symptom inventory-short form. J Pain Symptom Manage 27:14–23PubMedCentralPubMedCrossRefGoogle Scholar
  42. 42.
    von Haehling S, Morley JE, Anker SD (2010) An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachex Sarcopenia Muscle 1:129–133CrossRefGoogle Scholar
  43. 43.
    Ware JE Jr, Sherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30:473–483PubMedCrossRefGoogle Scholar
  44. 44.
    Weinfurt KP, Li Y, Castel LD, Saad F, Timbie JW, Glendenning GA, Schulman KA (2005) The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 16:579–584PubMedCrossRefGoogle Scholar
  45. 45.
    Wickham C, Cooper C, Margetts BM, Barker DJ (1989) Muscle strength, activity, housing, and the risk of falls in elderly people. Age Aging 18:47–51CrossRefGoogle Scholar
  46. 46.
    Yu HH, Tsai YY, Hoffe SE (2012) Overview of diagnosis and management of metastatic disease to bone. Cancer Control 19:84–91PubMedGoogle Scholar
  47. 47.
    Zabora J, BrintzenhofeSzoc K, Jacobsen P, Curbow B, Piantadosi S, Hooker C, Owens A, Derogatis L (2001) A new psychosocial screening instrument for use with cancer patients. Psychosomatics 42:241–246PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Prue Cormie
    • 1
    Email author
  • Daniel A. Galvão
    • 1
  • Nigel Spry
    • 1
    • 2
    • 3
  • David Joseph
    • 1
    • 2
    • 3
  • Dennis R. Taaffe
    • 1
    • 4
  • Robert U. Newton
    • 1
  1. 1.Edith Cowan University Health and Wellness Institute, Edith Cowan UniversityJoondalupAustralia
  2. 2.Department of Radiation OncologySir Charles Gairdner HospitalNedlandsAustralia
  3. 3.Faculty of MedicineUniversity of Western AustraliaNedlandsAustralia
  4. 4.School of Environmental and Life SciencesUniversity of NewcastleOurimbahAustralia

Personalised recommendations